Jim Wassil Sells 1,381 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 1,381 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $61.16, for a total value of $84,461.96. Following the transaction, the executive vice president directly owned 152,228 shares of the company’s stock, valued at approximately $9,310,264.48. The trade was a 0.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The stock was sold at an average price of $59.52, for a total value of $79,399.68.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total value of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total value of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total transaction of $126,742.50.

Vaxcyte Stock Performance

PCVX stock opened at $58.90 on Friday. The firm has a fifty day moving average price of $58.42 and a 200 day moving average price of $56.32. Vaxcyte, Inc. has a fifty-two week low of $30.81 and a fifty-two week high of $65.00. The firm has a market cap of $8.76 billion, a PE ratio of -7.72 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter in the previous year, the company posted ($1.22) EPS. On average, equities analysts predict that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on PCVX shares. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Finally, Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Vaxcyte presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its holdings in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares during the last quarter. IFP Advisors Inc boosted its position in shares of Vaxcyte by 72.8% during the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock valued at $33,000 after buying an additional 236 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after buying an additional 184 shares during the period. Finally, CIBC Private Wealth Group LLC grew its stake in shares of Vaxcyte by 22,500.0% during the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after buying an additional 1,350 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc is a clinical-stage biotechnology company focused on developing vaccines to prevent serious bacterial infections. The company’s lead programs target pneumococcal disease, which can cause pneumonia, meningitis, bloodstream infections and other invasive illnesses. Vaxcyte is developing broad-spectrum pneumococcal conjugate vaccine candidates designed to protect against a wide range of bacterial serotypes.

Vaxcyte’s pipeline has included VAX-24, an investigational 24-valent pneumococcal conjugate vaccine, and VAX-31, a next-generation candidate designed to cover 31 serotypes.